Construct: ORF ccsbBroad304_11606
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF012690.1_s304c1, BRDN0000460386
- Derived from:
- ccsbBroadEn_11606
- DNA Barcode:
- None
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- RABL2A (11159)
Vector Information:
- Vector Backbone:
- pLX_304
- Pol II Cassette 1:
- PGK-BlastR
- Pol II Cassette 2:
- CMV-ccsbBroad304_11606
- Selection Marker:
- BlastR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306161.2 | 99.5% | 98.7% | 80T>C;305A>G |
| 2 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354421.2 | 99.5% | 98.7% | 80T>C;305A>G |
| 3 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354423.2 | 99.5% | 98.7% | 80T>C;305A>G |
| 4 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003226.1 | 99.5% | 98.7% | 80T>C;305A>G |
| 5 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354424.2 | 98.9% | 98.1% | 80T>C;216_217insGCA;302A>G |
| 6 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354418.2 | 93.9% | 93.1% | 80T>C;305A>G;313_342del |
| 7 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354419.2 | 93.9% | 93.1% | 80T>C;305A>G;313_342del |
| 8 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003223.1 | 93.9% | 93.1% | 80T>C;305A>G;313_342del |
| 9 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354416.2 | 72% | 71% | (many diffs) |
| 10 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_007082.5 | 72% | 71% | (many diffs) |
| 11 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_013412.4 | 72% | 71% | (many diffs) |
| 12 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003220.1 | 72% | 71% | (many diffs) |
| 13 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003222.1 | 72% | 71% | (many diffs) |
| 14 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306158.2 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 15 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306159.2 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 16 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354412.2 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 17 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354413.2 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 18 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354414.2 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 19 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003213.1 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 20 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003214.1 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 21 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003215.1 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 22 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003216.1 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 23 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452575.1 | 71.7% | 71.1% | 80T>C;217_408del;497A>G |
| 24 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130922.3 | 71.6% | 70.1% | (many diffs) |
| 25 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350005.2 | 71.6% | 70.1% | (many diffs) |
| 26 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350006.2 | 71.6% | 70.1% | (many diffs) |
| 27 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350007.2 | 71.6% | 70.1% | (many diffs) |
| 28 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_007081.4 | 71.6% | 70.1% | (many diffs) |
| 29 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028556.1 | 71.6% | 70.1% | (many diffs) |
| 30 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001003789.3 | 71.3% | 70.3% | (many diffs) |
| 31 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130919.3 | 71.3% | 70.3% | (many diffs) |
| 32 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130920.3 | 71.3% | 70.3% | (many diffs) |
| 33 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130921.3 | 71.3% | 70.3% | (many diffs) |
| 34 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350003.2 | 71.3% | 70.3% | (many diffs) |
| 35 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350004.2 | 71.3% | 70.3% | (many diffs) |
| 36 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028552.1 | 71.3% | 70.3% | (many diffs) |
| 37 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028555.1 | 71.3% | 70.3% | (many diffs) |
| 38 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_024452147.1 | 71.3% | 70.3% | (many diffs) |
| 39 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354427.2 | 71.1% | 57.9% | (many diffs) |
| 40 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003212.1 | 70.2% | 69.2% | (many diffs) |
| 41 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003210.1 | 69.9% | 69.3% | (many diffs) |
| 42 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003211.1 | 69.9% | 69.3% | (many diffs) |
| 43 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028551.1 | 69.8% | 68.3% | (many diffs) |
| 44 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350016.2 | 69.5% | 68.5% | (many diffs) |
| 45 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350017.2 | 69.5% | 68.5% | (many diffs) |
| 46 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354417.2 | 69.2% | 68.5% | (many diffs) |
| 47 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306160.3 | 69% | 68% | (many diffs) |
| 48 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354410.2 | 69% | 68% | (many diffs) |
| 49 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452573.1 | 69% | 68% | (many diffs) |
| 50 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354405.2 | 68.7% | 68.2% | (many diffs) |
| 51 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354406.2 | 68.7% | 68.2% | (many diffs) |
| 52 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354407.2 | 68.7% | 68.2% | (many diffs) |
| 53 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354408.2 | 68.7% | 68.2% | (many diffs) |
| 54 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354409.2 | 68.7% | 68.2% | (many diffs) |
| 55 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712208.3 | 68.7% | 68.2% | (many diffs) |
| 56 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712209.3 | 68.7% | 68.2% | (many diffs) |
| 57 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_011510509.2 | 68.7% | 68.2% | (many diffs) |
| 58 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003203.1 | 68.7% | 68.2% | (many diffs) |
| 59 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003204.1 | 68.7% | 68.2% | (many diffs) |
| 60 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003205.1 | 68.7% | 68.2% | (many diffs) |
| 61 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003207.1 | 68.7% | 68.2% | (many diffs) |
| 62 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130923.3 | 68.6% | 67.2% | (many diffs) |
| 63 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350013.2 | 68.6% | 67.2% | (many diffs) |
| 64 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350014.2 | 68.6% | 67.2% | (many diffs) |
| 65 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350015.2 | 68.6% | 67.2% | (many diffs) |
| 66 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028547.1 | 68.6% | 67.2% | (many diffs) |
| 67 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354426.2 | 68.5% | 53.7% | (many diffs) |
| 68 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350008.2 | 68.3% | 67.3% | (many diffs) |
| 69 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350009.2 | 68.3% | 67.3% | (many diffs) |
| 70 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350010.2 | 68.3% | 67.3% | (many diffs) |
| 71 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350011.2 | 68.3% | 67.3% | (many diffs) |
| 72 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350012.2 | 68.3% | 67.3% | (many diffs) |
| 73 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028543.1 | 68.3% | 67.3% | (many diffs) |
| 74 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028544.1 | 68.3% | 67.3% | (many diffs) |
| 75 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028546.1 | 68.3% | 67.3% | (many diffs) |
| 76 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452576.1 | 67.2% | 54.8% | (many diffs) |
| 77 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354428.2 | 67% | 58.2% | (many diffs) |
| 78 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354425.2 | 64.8% | 51% | (many diffs) |
| 79 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003230.1 | 64.8% | 51% | (many diffs) |
| 80 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028559.2 | 58.4% | 47.3% | (many diffs) |
| 81 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148880.2 | 25% | (many diffs) | |
| 82 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148879.2 | 24.3% | (many diffs) | |
| 83 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148882.2 | 24.2% | (many diffs) | |
| 84 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148881.2 | 24.2% | (many diffs) | |
| 85 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XR_002959036.1 | 19.7% | (many diffs) | |
| 86 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521327.3 | 46.1% | 43.6% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 69
- ORF end:
- 564
- ORF length:
- 495
- Sequence:
-
1 ggtctatata agcagagctc tctggctaac tgtcgggatc aacaagtttg tacaaaaaag 61 ttggcaccat ggcagaagac aaaaccaaac cgagtgagtt ggaccaaggg aagtatgatg 121 ctgatgacaa cgtgaagatc atctgcccgg gagacagcgc agtgggcaaa tccaaactca 181 tggagagatt tctcatggat ggctttcagc cacagcagct gtccacgtac gccctgaccc 241 tgtacaagca cacagccacg gtagatggca agaccatcct tgtggcagac ataaacgtga 301 cccaaaaaag cttcaatttt gccaagaagt tctccctgcc cctgtatttc gtctcggctg 361 ctgatggtac cagtgttgtg aagctcttca atgatgcaat tcgattagct gtgtcttaca 421 aacagaactc ccaggacttc atggatgaga tttttcagga gctcgagaac ttcagcttgg 481 agcaggaaga ggaggacgtg ccagaccagg aacagagcag cagcatcgag accccatcag 541 aggaggtggc ctctccccac agcttgccaa ctttcttgta caaagtggtt ggtaagccta 601 tccctaaccc tctcctcggt ctcgattcta cgtagtaatg agctagcgct aaccggtggc 661 gcgttaagtc gacaatcaac ctctggatta